颞骨鳞状细胞癌的免疫组织化学标志物表达。
Immunohistochemical Marker Expression in Temporal Bone Squamous Cell Carcinoma.
机构信息
Department of Otolaryngology-Head and Neck Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
出版信息
Tokai J Exp Clin Med. 2021 Jul 20;46(2):89-93.
BACKGROUND
The correlation between genomic mutations (or the overexpression of abnormal proteins) and prognosis in temporal bone squamous cell carcinoma (TBSCC) is not clear. We investigated the overexpression of EGFR and p53 as a pathological biomarker for predicting the clinical course of patients with TBSCC.
METHODS
We performed a retrospective review of 22 TBSCC cases treated in Tokai University Hospital between January 2005 and October 2016. We assessed the overexpression of EGFR and p53 in TBSCC patients through immunohistochemical staining. We also evaluated the association between the overexpression of these proteins and clinicopathological variables, including survival outcomes.
RESULTS
The primary lesion in all patients was the external auditory canal. Nine (40.9%) patients were EGFR positive, and 9 (40.9%) were p53 positive. The 5-year overall survival rate for EGFR-positive patients (55.6%) was significantly lower (p = 0.043) than that of the EGFR-negative patients (92.3%).
CONCLUSION
EGFR overexpression in TBSCC patients may be a prognostic biomarker.
背景
在颞骨鳞状细胞癌（TBSCC）中，基因组突变（或异常蛋白的过表达）与预后之间的相关性尚不清楚。我们研究了 EGFR 和 p53 的过表达作为预测 TBSCC 患者临床病程的病理生物标志物。
方法
我们对 2005 年 1 月至 2016 年 10 月在东海大学医院治疗的 22 例 TBSCC 病例进行了回顾性研究。我们通过免疫组织化学染色评估 TBSCC 患者中 EGFR 和 p53 的过表达。我们还评估了这些蛋白的过表达与临床病理变量之间的关系，包括生存结果。
结果
所有患者的原发性病变均在外耳道。9 例（40.9%）患者 EGFR 阳性，9 例（40.9%）患者 p53 阳性。EGFR 阳性患者的 5 年总生存率（55.6%）明显低于 EGFR 阴性患者（92.3%）（p=0.043）。
结论
TBSCC 患者中 EGFR 的过表达可能是一种预后生物标志物。
Zotero 插件